Literature DB >> 17403071

The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study.

Yasser Shaib1, Jessica Davila, Chris Naumann, Hashem El-Serag.   

Abstract

OBJECTIVES: Pancreatic cancer is the fourth leading cause of cancer death in the United States. Curative intent surgery (CIS) is presumed to be the only curative option in the treatment of pancreatic cancer. The determinants and the outcomes of surgical resection are not clear at the population level.
METHODS: Using data from nine registries of the Surveillance Epidemiology and End Results (SEER) program, we examined the predictors of receiving CIS as well as the survival of patients receiving CIS between 1987 and 2001. The definition of CIS in SEER is accurate and has been previously validated and found to be highly accurate. Cox proportional hazard model was used to examine the effect of potential determinants on survival.
RESULTS: We identified 32,348 cases of pancreatic cancer. Of those, 3,545 (10.9%) received CIS. The proportion of patients receiving CIS decreased significantly with age (P < 0.0001), was similar across all racial groups (10.8% in whites, 11.4% in blacks, 11.5% in Asians, and 11.2 % in Hispanics, P= 0.5), was slightly higher in men (11.3%vs 10.5%, P= 0.02), decreased with advanced disease stage (P < 0.0001), progressively increased over time (7.5% in 1987-89, 9.1% in 1990-92, 10.4% in 1993-95, 12.4% in 1996-98, and 13.4% in 1999-2001, P < 0.0001), and differed significantly across different SEER registries (9.7% in San Francisco, 11.8% in Connecticut, 12.5% in Detroit, 11.7% in Hawaii, 9.3% in Iowa, 10.05% in New Mexico, 9.5% in Seattle, 13.2% in Utah, 11.4% in Atlanta, P < 0.0001). In the multivariable logistic regression analysis, more recent time periods, younger age, early disease stage, and geographic location, but not race or gender, were independent predictors of receiving CIS. In the Cox survival analysis, younger age, early disease stage, more recent time period, geographic location, and receipt of CIS were independent predictors of improved survival and black race was an independent predictor of shorter survival.
CONCLUSIONS: Early stage disease, female gender, younger age, geographic location, and more recent time periods are predictors of receiving CIS. Early disease stage and receipt of CIS are the strongest predictors of improved survival among patients with pancreatic cancer. Black race is an independent predictor of shorter survival.

Entities:  

Mesh:

Year:  2007        PMID: 17403071     DOI: 10.1111/j.1572-0241.2007.01202.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

Review 1.  Surgical outcome of adenosquamous carcinoma of the pancreas.

Authors:  Takehiro Okabayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

2.  Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors:  S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 3.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

4.  Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer.

Authors:  Michael Bau Mortensen; Claus Fristrup; Alan Ainsworth; Henning Overgaard Nielsen; Torsten Pless; Claus Hovendal
Journal:  Surg Endosc       Date:  2010-07-30       Impact factor: 4.584

5.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

6.  Advanced pancreatic cancer - how to choose an adequate treatment option.

Authors:  Eija A Korkeila
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

7.  National disparities in minimally invasive surgery for pancreatic tumors.

Authors:  Emmanuel Gabriel; Pragatheeshwar Thirunavukarasu; Kristopher Attwood; Steven J Nurkin
Journal:  Surg Endosc       Date:  2016-07-13       Impact factor: 4.584

8.  Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China.

Authors:  Yong Chen; JiHui Hao; WeiDong Ma; Yong Tang; ChunTao Gao; XiShan Hao
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

Review 9.  Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.

Authors:  Madeline T Olson; Quan P Ly; Aaron M Mohs
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

10.  Surgery for pancreatic carcinoma: state of the art.

Authors:  Shailesh V Shrikhande; Savio George Barreto
Journal:  Indian J Surg       Date:  2011-11-24       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.